iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sun Pharmaceuticals Industries Ltd Option Chain

1,832.3
(1.48%)
Apr 30, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ol (lots)Call PriceStrike PricePut PriceOl (lots)
1,0500%₹2450%1,340₹0.050%5,250-16.66%
--1,350₹0.05-75%15,400-2.22%
--1,360₹0.1-50%29,750-8.60%
--1,380₹0.050%73,5000%
--1,390₹0.05-66.66%20,6500%
3500%₹184.150%1,400₹0.050%65,450-1.57%
--1,410₹0.050%8,4000%
--1,420₹0.05-50%25,200-2.70%
--1,430₹0.05-90.9%12,6000%
2,1000%₹121.30%1,440₹0.05-50%15,050-20.37%
15,050-4.44%₹201.7528.58%1,450₹0.050%59,150-2.31%
10,8500%₹1250%1,460₹0.050%51,100-9.31%
12,2500%₹139.40%1,470₹0.05-50%35,700-5.55%
14,7000%₹17438.2%1,480₹0.050%39,550-9.6%
11,5500%₹1280%1,490₹0.050%19,6000%
59,500-1.73%₹152.2532.39%1,500₹0.050%1,72,550-4.45%
24,8500%₹96.26.59%1,510₹0.050%56,000-1.23%
1,27,050-1.89%₹1026.91%1,520₹0.050%3,64,350-4.49%
88,550-1.55%₹14577.15%1,530₹0.1100%70,700-9.82%
10,07,650-0.20%₹13180.06%1,540₹0.050%2,99,950-6.94%
1,32,650-0.52%₹99.957.44%1,550₹0.050%2,23,300-0.77%
5,07,850-0.41%₹101.4587.69%1,560₹0.05-66.66%2,05,800-12.36%
86,100-2.38%₹96.1126.11%1,570₹0.05-66.66%2,21,200-17.92%
2,47,100-5.61%₹73.6122.35%1,580₹0.05-50%2,14,900-11.90%
3,65,400-0.28%₹50104.49%1,590₹0.05-80%2,85,950-5%
18,14,750-1.25%₹55.1271.04%1,600₹0.05-94.44%9,03,700-7.98%
1,12,350-19.14%₹44.15396.06%1,610₹0.3-94.78%92,750-11.37%
53,200-67.93%₹36537.16%1,620₹0.05-99.55%63,000-24.68%
56,000-66.73%₹23.8580%1,630₹0.05-99.75%70,0008.69%
84,000-49.04%₹14.05368.33%1,640₹0.3-98.93%47,950-10.45%
40,250-68.49%₹0.05-96.55%1,660₹2.25-97.2%42,35047.56%
28,000-49.36%₹0.05-93.33%1,680₹10.15-84.28%15,4000%
1,33,000-47.87%₹0.1-80%1,700₹112.70%1,4000%
67,2000%₹0.10%1,720₹130.650%2,1000%
5,6000%₹0.70%1,740--
1,05,0000%₹0.050%1,760₹2350%00%
12,9500%₹0.050%1,800--
2,1000%₹0.050%1,840--

Sun Pharma.Inds.: Related NEWS

Sun Pharma’s MM-II Trial Shows Long-Lasting Relief for Knee Osteoarthritis
26 Apr 2025|01:15 PM

Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.

Read More
Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million
10 Mar 2025|10:46 AM

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

Read More
Sun Pharma Q3 Profit Jumps 19% YoY, Declares ₹10.50 Dividend
31 Jan 2025|10:17 PM

An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.

Read More
Sun Pharma reports Q2 net profit at ₹3,040 Crore
29 Oct 2024|10:30 AM

Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.

Read More
Sun Pharma's Hair Loss Drug Approved by USFDA
26 Jul 2024|01:45 PM

The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.

Read More
Mayne Pharma Sues Sun Pharma in Patent Dispute
25 Jul 2024|11:57 AM

IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.

Read More
USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|11:24 AM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.